Inotrem is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.
Inotrem identified the TREM-1 pathway as a key factor causing unbalanced inflammatory responses. The company focuses on the therapeutic tools derived from knowledge of the biology of TREM-1 pathway.
Through its proprietary technology platform, Inotrem has developed the first-in-class clinical TREM-1 inhibitor, nangibotide (LR12), with applications in a number of indications such as septic shock or myocardial infarction.
INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases.
A first clinical trial to assess the safety, tolerability and pharmacokinetics of MOTREM in healthy volunteers is currently ongoing.
Paris, Limoges, Nancy (France). February 3rd, 2021 – Today, the CoviTREM-1 consortium, regrouping Nancy and Limoges teaching hospitals with Inotrem, a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, announces that it has completed
Paris, Limoges, Nancy (France). February 3rd, 2021 – Today, the CoviTREM-1 consortium, regrouping Nancy and Limoges teaching hospitals with Inotrem, a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, announces that it has completed
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2018 – Legal notices
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices